Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.
Gerson JN, Ramamurthy C, Borghaei H
Managing adverse effects of immunotherapy
Clin Adv Hematol Oncol (2018) 16:364-374.
Remarkable efficacy has been achieved in a variety of cancer types by targeting immune checkpoints. The cytotoxic T-lymphocyte-associated antigen 4 inhibitor ipilimumab, the programmed death 1 inhibitors nivolumab and pembrolizumab, and the programmed death ligand 1 inhibitors atezolizumab, avelumab, and durvalumab are the agents currently approved by the US Food and Drug Administration for the treatment of certain advanced malignancies. These agents mark a departure from both standard cytotoxic chemotherapy and targeted therapy. However, they are associated with a unique set of immune-related adverse events (irAEs), which can manifest as a wide range of autoimmune phenomena. The irAEs can affect any system in the body and in rare cases are life-threatening. It is critical for the practicing medical oncologist to recognize and promptly treat any irAEs that may develop.
Publication Date: 2018-05-01.
PMCID: Review
Last updated on Thursday, July 09, 2020